|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
CA2362937C
(fr)
*
|
1999-02-24 |
2011-03-22 |
The Uab Research Foundation |
Derives de taxane pour therapie ciblee contre le cancer
|
|
AU775373B2
(en)
*
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
NZ517772A
(en)
*
|
1999-11-24 |
2004-03-26 |
Immunogen Inc |
Cytotoxic agents comprising taxanes and their therapeutic use
|
|
US7097840B2
(en)
*
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
AU2001288805A1
(en)
*
|
2000-09-22 |
2002-04-02 |
Bristol-Myers Squibb Company |
Method for reducing toxicity of combined chemotherapies
|
|
WO2002049672A2
(fr)
*
|
2000-12-21 |
2002-06-27 |
Mcgill University |
Compose utilise pour cibler des cellules specifiques a toxicite systemique reduite
|
|
WO2002076394A2
(fr)
*
|
2001-03-22 |
2002-10-03 |
The Ohio State University Research Foundation |
Compositions anticancereuses a base d'enzymes et techniques
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
US7589180B2
(en)
|
2001-05-11 |
2009-09-15 |
Abbott Laboratories Inc. |
Specific binding proteins and uses thereof
|
|
US7666414B2
(en)
*
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
|
US7514078B2
(en)
*
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
|
IL158969A0
(en)
*
|
2001-06-01 |
2004-05-12 |
Cornell Res Foundation Inc |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
|
US6596757B1
(en)
*
|
2002-05-14 |
2003-07-22 |
Immunogen Inc. |
Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
|
|
JP2005533794A
(ja)
*
|
2002-06-18 |
2005-11-10 |
アーケミックス コーポレイション |
アプタマー−毒素分子およびこれを使用する方法
|
|
EP1536814A4
(fr)
*
|
2002-07-03 |
2006-02-15 |
Immunogen Inc |
Anticorps contre muc1 et muc16 non liberees et leurs utilisations
|
|
CA2494074A1
(fr)
*
|
2002-08-02 |
2004-02-12 |
Immunogen, Inc. |
Agents cytotoxiques renfermant des nouveaux taxanes puissants et utilisation therapeutique de ceux-ci
|
|
US7390898B2
(en)
*
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
|
DE60336149D1
(de)
*
|
2002-08-16 |
2011-04-07 |
Immunogen Inc |
Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
|
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
BRPI0410260A
(pt)
|
2003-05-14 |
2006-05-16 |
Immunogen Inc |
composição conjugada para medicamento
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7834155B2
(en)
|
2003-07-21 |
2010-11-16 |
Immunogen Inc. |
CA6 antigen-specific cytotoxic conjugate and methods of using the same
|
|
CN103145844B
(zh)
*
|
2003-07-21 |
2016-08-03 |
伊缪诺金公司 |
Ca6抗原特异性细胞毒性偶联物及其应用方法
|
|
US7282590B2
(en)
*
|
2004-02-12 |
2007-10-16 |
The Research Foundation Of State University Of New York |
Drug conjugates
|
|
WO2005094882A1
(fr)
*
|
2004-03-03 |
2005-10-13 |
Millennium Pharmaceuticals, Inc. |
Anticorps modifies diriges contre un antigene membranaire specifique de la prostate
|
|
US7541330B2
(en)
*
|
2004-06-15 |
2009-06-02 |
Kosan Biosciences Incorporated |
Conjugates with reduced adverse systemic effects
|
|
WO2006012527A1
(fr)
|
2004-07-23 |
2006-02-02 |
Endocyte, Inc. |
Groupes de liaison bivalents et conjugués de ceux-ci
|
|
US20060045877A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Goldmakher Viktor S |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
|
EP1669358A1
(fr)
*
|
2004-12-07 |
2006-06-14 |
Aventis Pharma S.A. |
Agents cytotoxiques comprenant des nouveau taxanes
|
|
EP1688415A1
(fr)
*
|
2004-12-07 |
2006-08-09 |
Aventis Pharma S.A. |
Agents cytotoxiques comprenant des taxanes modifiés en position C2
|
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
|
ES2503719T3
(es)
|
2005-02-11 |
2014-10-07 |
Immunogen, Inc. |
Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
|
|
EP1868647A4
(fr)
|
2005-03-24 |
2009-04-01 |
Millennium Pharm Inc |
Anticorps se liant à ov064 et leurs méthodes d'utilisation
|
|
JP2009503105A
(ja)
|
2005-08-03 |
2009-01-29 |
イミュノジェン・インコーポレーテッド |
免疫複合体製剤
|
|
ES2468240T3
(es)
*
|
2005-08-19 |
2014-06-16 |
Endocyte, Inc. |
Conjugados de ligando de múltiples fármacos
|
|
IL305084A
(en)
*
|
2005-08-24 |
2023-10-01 |
Immunogen Inc |
A process for preparing purified drug compounds
|
|
EP1806365A1
(fr)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
|
|
EP1813614B1
(fr)
|
2006-01-25 |
2011-10-05 |
Sanofi |
Agents cytotoxiques comprenant de nouveaux dérivés de Tomaymycine
|
|
USRE47123E1
(en)
*
|
2006-07-18 |
2018-11-13 |
Sanofi |
EPHA2 receptor antagonist antibodies
|
|
EP1914242A1
(fr)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Nouveau anticorps Anti-CD38 pour le traitement du cancer
|
|
US8470332B2
(en)
|
2006-11-22 |
2013-06-25 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
|
MX338185B
(es)
*
|
2007-01-25 |
2016-04-05 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
|
US20100144599A1
(en)
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
|
US20080184892A1
(en)
|
2007-02-06 |
2008-08-07 |
Ctp Hydrogen Corporation |
Architectures for electrochemical systems
|
|
WO2008101231A2
(fr)
|
2007-02-16 |
2008-08-21 |
Endocyte, Inc. |
Procédés et compositions de traitement et de diagnostic d'une maladie rénale
|
|
CN101678124A
(zh)
|
2007-03-14 |
2010-03-24 |
恩多塞特公司 |
结合配体连接的微管溶素递药缀合物
|
|
WO2008115404A1
(fr)
*
|
2007-03-15 |
2008-09-25 |
Ludwing Institute For Cancer Research |
Procédé de traitement utilisant des anticorps d'egfr et des inhibiteurs de src, et formulations en rapport
|
|
CN101715342A
(zh)
*
|
2007-03-19 |
2010-05-26 |
因弗拉布洛克制药公司 |
钴胺素紫杉烷生物结合物
|
|
EP3569251A1
(fr)
|
2007-06-25 |
2019-11-20 |
Endocyte, Inc. |
Conjugués contenant des lieurs espaceurs hydrophiles
|
|
US9877965B2
(en)
|
2007-06-25 |
2018-01-30 |
Endocyte, Inc. |
Vitamin receptor drug delivery conjugates for treating inflammation
|
|
PL2019104T3
(pl)
*
|
2007-07-19 |
2014-03-31 |
Sanofi Sa |
Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
|
|
PE20120259A1
(es)
|
2007-08-09 |
2012-04-04 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
|
EP2188311B1
(fr)
|
2007-08-14 |
2016-10-05 |
Ludwig Institute for Cancer Research Ltd. |
Anticorps monoclonal 175 ciblant le récepteur egf et dérivées et utilisations de ceux-ci
|
|
US20100291113A1
(en)
*
|
2007-10-03 |
2010-11-18 |
Cornell University |
Treatment of Proliferative Disorders Using Antibodies to PSMA
|
|
PL2801584T3
(pl)
|
2007-12-26 |
2019-12-31 |
Biotest Ag |
Środki mające za cel CD138 i ich zastosowania
|
|
CN101965366B
(zh)
*
|
2007-12-26 |
2016-04-27 |
生物测试股份公司 |
靶向cd138的免疫缀合物及其应用
|
|
EP2240516B1
(fr)
*
|
2007-12-26 |
2015-07-08 |
Biotest AG |
Procédés et agents permettant d'améliorer le ciblage de cellules tumorales exprimant cd138
|
|
WO2009080831A1
(fr)
*
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Procédé permettant de réduire les effets secondaires cytotoxiques et d'améliorer l'efficacité des immunoconjugués
|
|
EP2278963A4
(fr)
*
|
2008-01-16 |
2014-09-17 |
Anwar Rayan |
Dérivés de taxol et composés étroitement apparentés
|
|
CA3146422A1
(fr)
|
2008-03-18 |
2009-09-24 |
Genentech, Inc. |
Combinaisons de conjugues anticorps anti-her2-medicament et d'agents chimiotherapiques, et procedes d'utilisation
|
|
KR20210100223A
(ko)
|
2008-04-30 |
2021-08-13 |
이뮤노젠 아이엔씨 |
가교제 및 그 용도
|
|
JP2011520961A
(ja)
|
2008-05-22 |
2011-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
多価フィブロネクチンをベースとする足場ドメインタンパク質
|
|
BRPI1008749B8
(pt)
|
2009-02-05 |
2021-05-25 |
Immunogen Inc |
compostos derivados de benzodiazepina, seus conjugados, composição farmacêutica, seu uso e seus processos de preparação
|
|
ES2712732T3
(es)
*
|
2009-02-17 |
2019-05-14 |
Cornell Res Foundation Inc |
Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
|
|
CA2939492C
(fr)
|
2009-05-13 |
2019-03-19 |
Genzyme Corporation |
Immunoglobulines anti-cd52 humain
|
|
LT2437790T
(lt)
|
2009-06-03 |
2019-06-10 |
Immunogen, Inc. |
Konjugavimo būdai
|
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
|
JP2013506709A
(ja)
|
2009-10-06 |
2013-02-28 |
イミュノジェン・インコーポレーテッド |
有効なコンジュゲートおよび親水性リンカー
|
|
EA201792376A3
(ru)
|
2009-10-23 |
2018-08-31 |
Милленниум Фармасьютикалз, Инк. |
Молекулы анти-gcc антитела и соответствующие композиции и способы
|
|
MX341687B
(es)
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
"anticuerpos cd20 y su utilización".
|
|
PH12018501083A1
(en)
|
2010-03-04 |
2019-02-18 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
PT2552959T
(pt)
|
2010-03-26 |
2017-04-21 |
Memorial Sloan Kettering Cancer Center |
Anticorpos para muc16 e métodos de utilização dos mesmos
|
|
US9133239B2
(en)
|
2010-04-20 |
2015-09-15 |
The Research Foundation For The State University Of New York |
Compositions and methods for inhibiting matrix metalloproteinase (MMP)-mediated cell migration
|
|
EA201390575A1
(ru)
|
2010-10-29 |
2014-01-30 |
Иммьюноджен, Инк. |
Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
|
|
SG189929A1
(en)
|
2010-10-29 |
2013-06-28 |
Immunogen Inc |
Novel egfr-binding molecules and immunoconjugates thereof
|
|
WO2012075173A2
(fr)
|
2010-12-01 |
2012-06-07 |
Board Of Regents The University Of Texas System |
Compositions et procédé de désimmunisation de protéines
|
|
ES2602118T3
(es)
|
2010-12-09 |
2017-02-17 |
Immunogen, Inc. |
Métodos para la preparación de agentes de reticulación cargados
|
|
US9433686B2
(en)
|
2011-01-31 |
2016-09-06 |
The Regents Of The University Of California |
Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function
|
|
EP3666289A1
(fr)
|
2011-02-15 |
2020-06-17 |
ImmunoGen, Inc. |
Dérivés de benzodiazépine cytotoxique
|
|
KR20220009505A
(ko)
|
2011-03-29 |
2022-01-24 |
이뮤노젠 아이엔씨 |
일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
|
|
WO2012135517A2
(fr)
|
2011-03-29 |
2012-10-04 |
Immunogen, Inc. |
Préparation de conjugués de maytansinoïde anticorps par procédé en une étape
|
|
EP2714733B1
(fr)
|
2011-05-21 |
2019-01-23 |
MacroGenics, Inc. |
Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
|
|
MX368966B
(es)
|
2011-06-10 |
2019-10-23 |
Mersana Therapeutics Inc |
Conjugados de proteina-polimero-farmaco.
|
|
JP6209159B2
(ja)
|
2011-06-21 |
2017-10-04 |
イミュノジェン・インコーポレーテッド |
ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体
|
|
ES2806146T3
(es)
|
2011-09-22 |
2021-02-16 |
Amgen Inc |
Proteínas de unión al antígeno CD27L
|
|
CN104066481A
(zh)
|
2011-11-21 |
2014-09-24 |
伊缪诺金公司 |
利用egfr抗体细胞毒性剂缀合物治疗抗egfr疗法的肿瘤的方法
|
|
EP2788030B1
(fr)
|
2011-12-08 |
2018-06-20 |
Biotest AG |
Utilisations d'immunoconjugués ciblant cd138
|
|
US10080805B2
(en)
|
2012-02-24 |
2018-09-25 |
Purdue Research Foundation |
Cholecystokinin B receptor targeting for imaging and therapy
|
|
US20140080175A1
(en)
|
2012-03-29 |
2014-03-20 |
Endocyte, Inc. |
Processes for preparing tubulysin derivatives and conjugates thereof
|
|
JP2015516980A
(ja)
|
2012-04-26 |
2015-06-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｄ３７抗体とベンダムスチンとの併用
|
|
JP2015517511A
(ja)
|
2012-05-16 |
2015-06-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
|
|
JP2015517512A
(ja)
|
2012-05-16 |
2015-06-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｄ３７抗体の更なる薬剤との併用
|
|
JO3623B1
(ar)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
البروتينات المرتبطة بمولد المستضاد st2
|
|
JP6321633B2
(ja)
|
2012-06-04 |
2018-05-09 |
ノバルティス アーゲー |
部位特異的標識法およびそれによって生成される分子
|
|
SG11201502429YA
(en)
|
2012-10-04 |
2015-04-29 |
Immunogen Inc |
Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
|
|
AU2013331440A1
(en)
|
2012-10-16 |
2015-04-30 |
Endocyte, Inc. |
Drug delivery conjugates containing unnatural amino acids and methods for using
|
|
CA2891280C
(fr)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Lieurs hydrophiles et leurs utilisations pour la conjugaison de medicaments a des molecules se liant aux cellules
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
CA2892863C
(fr)
|
2012-12-10 |
2022-03-15 |
Mersana Therapeutics, Inc. |
Echafaudage polymere fonde sur des filaments helicoidaux apparies (phf) pour l'administration ciblee de medicaments
|
|
EP2928503B1
(fr)
|
2012-12-10 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Conjugués de composés auristatine
|
|
US9872918B2
(en)
|
2012-12-12 |
2018-01-23 |
Mersana Therapeutics, Inc. |
Hydroxyl-polymer-drug-protein conjugates
|
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
|
WO2014124258A2
(fr)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués
|
|
AU2014214751B2
(en)
|
2013-02-08 |
2017-06-01 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
NZ710929A
(en)
|
2013-03-15 |
2018-02-23 |
Novartis Ag |
Antibody drug conjugates
|
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
|
WO2014194274A2
(fr)
|
2013-05-30 |
2014-12-04 |
Biogen Idec Ma Inc. |
Protéines de liaison à l'antigène du récepteur de l'oncostatine m
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
JP6427564B2
(ja)
|
2013-10-11 |
2018-11-21 |
アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー |
タンパク質−ポリマー−薬物共役体
|
|
EP3054991B1
(fr)
|
2013-10-11 |
2019-04-03 |
Mersana Therapeutics, Inc. |
Conjugués de médicament-protéine-polymère
|
|
US9943606B2
(en)
|
2014-01-15 |
2018-04-17 |
Rutgers, The State University Of New Jersey |
Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
|
|
CN103804472B
(zh)
*
|
2014-01-23 |
2016-06-08 |
浙江大学 |
一种紫杉烷类药物前体
|
|
JP6533534B2
(ja)
|
2014-02-14 |
2019-06-19 |
マクロジェニクス，インコーポレーテッド |
膠芽腫の治療に使用するための組成物及びその使用
|
|
PT3122757T
(pt)
|
2014-02-28 |
2023-11-03 |
Hangzhou Dac Biotech Co Ltd |
Ligantes carregados e as suas utilizações em conjugação
|
|
US20170021033A1
(en)
|
2014-03-12 |
2017-01-26 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
|
WO2016020791A1
(fr)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Conjugués anticorps ckit-médicament
|
|
WO2016024195A1
(fr)
|
2014-08-12 |
2016-02-18 |
Novartis Ag |
Conjugués médicament-anticorps anti-cdh6
|
|
EP3189057A1
(fr)
|
2014-09-03 |
2017-07-12 |
ImmunoGen, Inc. |
Dérivés de benzodiazépine cytotoxique
|
|
CR20170111A
(es)
|
2014-09-03 |
2017-05-23 |
Immunogen Inc |
Derivados de benzodiazepina citotóxicos
|
|
GB201416960D0
(en)
|
2014-09-25 |
2014-11-12 |
Antikor Biopharma Ltd |
Biological materials and uses thereof
|
|
TN2017000173A1
(en)
|
2014-11-14 |
2018-10-19 |
Novartis Ag |
Antibody drug conjugates
|
|
WO2016090157A1
(fr)
|
2014-12-04 |
2016-06-09 |
Celgene Corporation |
Conjugués de biomolécule
|
|
WO2016149485A1
(fr)
|
2015-03-17 |
2016-09-22 |
The Regents Of The University Of California |
Nouvelle chimio-immunothérapie pour cancer épithélial
|
|
EP3271398B1
(fr)
|
2015-03-17 |
2022-08-31 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-muc16 et utilisations
|
|
US10548989B2
(en)
|
2015-04-07 |
2020-02-04 |
Memorial Sloan Kettering Cancer Center |
Nanoparticle immunoconjugates
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
RU2733740C2
(ru)
|
2015-06-29 |
2020-10-06 |
Иммуноджен, Инк. |
Конъюгаты сконструированных антител с цистеиновыми заменами
|
|
EP3319936A4
(fr)
|
2015-07-12 |
2019-02-06 |
Suzhou M-conj Biotech Co., Ltd. |
Lieux de pontage pour la conjugaison des molécules de liaison cellulaire
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
LT3325482T
(lt)
|
2015-07-21 |
2020-11-25 |
Immunogen, Inc. |
Citotoksinių benzodiazepino darinių paruošimo būdai
|
|
EP3331569A1
(fr)
|
2015-08-07 |
2018-06-13 |
Gamamabs Pharma |
Anticorps, conjugués anticorps-médicaments et procédés d'utilisation
|
|
AU2016332900C1
(en)
|
2015-09-29 |
2024-02-01 |
Amgen Inc. |
ASGR inhibitors
|
|
EP4335851A3
(fr)
|
2015-11-25 |
2024-06-05 |
ImmunoGen, Inc. |
Formulations pharmaceutiques et leurs procédés d'utilisation
|
|
WO2017194568A1
(fr)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Schéma de traitement utilisant un anticorps immunoconjugué anti-muc1 à base de maytansinoïde pour le traitement des tumeurs
|
|
JP7138350B2
(ja)
|
2016-11-14 |
2022-09-16 |
ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． |
共役連結体、該連結体を含有する細胞結合分子－薬物共役体、並びに該共役体及び連結体の使用及び製造方法
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
CN116813690A
(zh)
|
2016-11-23 |
2023-09-29 |
伊缪诺金公司 |
苯并二氮䓬衍生物的选择性磺化
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
RU2765098C2
(ru)
|
2017-02-28 |
2022-01-25 |
Иммуноджен, Инк. |
Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
|
|
WO2018185618A1
(fr)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement
|
|
US20180346488A1
(en)
|
2017-04-20 |
2018-12-06 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and conjugates thereof
|
|
WO2018201051A1
(fr)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
|
|
EP3641826B1
(fr)
|
2017-06-22 |
2023-12-06 |
Mersana Therapeutics, Inc. |
Procédés de production de matrices polymères transportant des médicaments, et conjugués protéine-polymère-médicament
|
|
US11530413B2
(en)
|
2017-07-21 |
2022-12-20 |
Novartis Ag |
Compositions and methods to treat cancer
|
|
JP2021508714A
(ja)
|
2017-12-28 |
2021-03-11 |
イミュノジェン・インコーポレーテッド |
ベンゾジアゼピン誘導体
|
|
JP2021514193A
(ja)
|
2018-02-21 |
2021-06-10 |
セルジーン コーポレイション |
Ｂｃｍａ結合抗体及びその使用
|
|
CN112839676A
(zh)
|
2018-10-10 |
2021-05-25 |
武田药品工业株式会社 |
制造抗体药物偶联物的方法
|
|
EA202191175A1
(ru)
|
2018-10-29 |
2021-09-08 |
Мерсана Терапьютикс, Инк. |
Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
|
|
WO2020089811A1
(fr)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Conjugué médicament-anticorps anti-dc-sign
|
|
EP3898697A2
(fr)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Anticorps dirigés contre pmel17 et conjugués de ces derniers
|
|
JP2022527151A
(ja)
|
2019-03-20 |
2022-05-31 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
クローディン６抗体及び薬物複合体
|
|
WO2020191344A1
(fr)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Anticorps de claudin-6 bispécifiques
|
|
TW202102506A
(zh)
|
2019-03-29 |
2021-01-16 |
美商伊繆諾金公司 |
苯二氮平衍生物
|
|
PT3958977T
(pt)
|
2019-04-26 |
2023-12-15 |
Immunogen Inc |
Derivados de camptotecina
|
|
MX2022008437A
(es)
|
2020-01-09 |
2022-08-19 |
Mersana Therapeutics Inc |
Conjugados fármaco-anticuerpo específicos de sitio con enlazadores que contienen péptidos.
|
|
KR20230004453A
(ko)
|
2020-02-25 |
2023-01-06 |
메디보스턴 리미티드 |
캄프토테신 유도체 및 이의 접합체
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
WO2022010797A2
(fr)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Nouveaux maytansinoïdes en tant que charges utiles d'adc et leur utilisation pour le traitement du cancer
|
|
EP3970752A1
(fr)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molécules ayant une étiquette de solubilité et procédés associés
|
|
MX2023006010A
(es)
|
2020-11-24 |
2023-06-08 |
Novartis Ag |
Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos.
|
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
|
EP4323526A1
(fr)
|
2021-04-16 |
2024-02-21 |
Novartis AG |
Conjugués anticorps-médicament et leurs procédés de fabrication
|
|
WO2024023735A1
(fr)
|
2022-07-27 |
2024-02-01 |
Mediboston Limited |
Dérivés d'auristatine et conjugués de ceux-ci
|